TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21761712

Group type: EXPERIMENTAL
Intervention: Telephone follow-up group A (79 patients)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Telephone follow-up group B (28 patients)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Telephone follow-up group C (24 patients)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (53 patients)
Number of subjects: 132
Study: 19094161

Group type: EXPERIMENTAL
Intervention: Gaboxadol 10 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Zolpidem 5 mg (active control)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 17349881

Group type: EXPERIMENTAL
Intervention: Ranolazine (500 to 1,000 mg twice daily)
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 746
Study: 15313288

Group type: EXPERIMENTAL
Intervention: Sharp-edged silicone intraocular lens (ClariFlex OptiEdge)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Round-edged silicone intraocular lens (PhacoFlex SI-40)
Number of subjects: 52
Study: 11759135

Group type: EXPERIMENTAL
Intervention: Word associations presented via headphones during anesthesia (Trivial Pursuit game statements)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control word associations (not specified in detail)
Number of subjects: 48
Study: 9251634

Group type: EXPERIMENTAL
Intervention: Combined treatment (sulphasalazine 2 g/day, methotrexate 7.5 mg/week, prednisolone initially 60 mg/day tapered to 7.5 mg/day)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Sulphasalazine alone
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Combined treatment
Number of subjects: 155
Study: 8329251

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 35

Group type: COMPARATOR
Intervention: Midazolam and Propofol
Number of subjects: 35
Study: 3574695

Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 0

Group type: COMPARATOR
Intervention: ECT
Number of subjects: 0
Study: 29431134

Group type: EXPERIMENTAL
Intervention: Brief intervention
Number of subjects: 2904

Group type: EXPERIMENTAL
Intervention: Programmatic non-pharmacological support
Number of subjects: 2904

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 2904

Group type: EXPERIMENTAL
Intervention: Intention to quit
Number of subjects: 2904

Group type: EXPERIMENTAL
Intervention: Vocational education
Number of subjects: 2904

Group type: EXPERIMENTAL
Intervention: High school education
Number of subjects: 2904

Group type: EXPERIMENTAL
Intervention: Chronic obstructive pulmonary disease
Number of subjects: 2904

Group type: EXPERIMENTAL
Intervention: Cardiovascular diseases
Number of subjects: 2904
Study: 27236335

Group type: EXPERIMENTAL
Intervention: Multicomponent programme for integrated management of chronic musculoskeletal pain and depression
Number of subjects: 330

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 330
Study: 24464791

Group type: EXPERIMENTAL
Intervention: Mupirocin/Chlorhexidine (M/C)
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Polymyxin/Tobramycin (P/T)
Number of subjects: 515
Study: 22369393

Group type: EXPERIMENTAL
Intervention: Lactobacillus (510 mg/day for a median of 4.0 days)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Non-exposed group (control)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Lactobacillus
Number of subjects: 304
Study: 20666950

Group type: EXPERIMENTAL
Intervention: 0.9% saline during bipolar resectoscopy
Number of subjects: 155

Group type: COMPARATOR
Intervention: 1.5% glycine during monopolar resectoscopy
Number of subjects: 155
Study: 18729669

Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 156
Study: 16192835

Group type: EXPERIMENTAL
Intervention: LY354740 (100 or 200 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paroxetine (60 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12007950

Group type: EXPERIMENTAL
Intervention: 18 Gy in 3 fractions on alternate days (6 Gy per fraction, Group A)
Number of subjects: 232

Group type: COMPARATOR
Intervention: 16 Gy in 2 fractions on alternate days (8 Gy per fraction, Group B)
Number of subjects: 232
Study: 12025819

Group type: EXPERIMENTAL
Intervention: Soft-start polymerization
Number of subjects: 30

Group type: COMPARATOR
Intervention: High-intensity halogen light
Number of subjects: 30
Study: 9790491

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Simpler forms of CBT
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Intensive individual CBT administered by a skilled therapist
Number of subjects: 2
Study: 7628649

Group type: EXPERIMENTAL
Intervention: Cochrane Collaboration in Primary Health Care
Number of subjects: 0
Study: 2562096

Group type: EXPERIMENTAL
Intervention: 0.5% plain bupivacaine (pH = 5.38 +/‐ 0.05)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine pH‐adjusted with 1.4% sodium bicarbonate (pH = 6.87 +/‐ 0.01)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with 1:200,000 epinephrine (pH = 4.80 +/‐ 0.04)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine pH‐adjusted with 1:200,000 epinephrine (pH = 6.68 +/‐ 0.01)
Number of subjects: 52

Group type: COMPARATOR
Intervention: All groups (including alkalinized solutions)
Number of subjects: 52
Study: 773481

Group type: EXPERIMENTAL
Intervention: Closed suction wound drainage
Number of subjects: 51

Group type: COMPARATOR
Intervention: Corrugated wound drainage
Number of subjects: 51
Study: 31481106

Group type: EXPERIMENTAL
Intervention: Riociguat (maximum of 2.5 mg three times daily)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 28820780

Group type: EXPERIMENTAL
Intervention: Exenatide (1‐h bolus of 0.05 µg/min followed by a constant infusion of 0.025 µg/min)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Insulin therapy (control group)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 104
Study: 25962863

Group type: EXPERIMENTAL
Intervention: Aortic valve calcifications present (n=657)
Number of subjects: 3111

Group type: EXPERIMENTAL
Intervention: Mitral valve/annulus calcifications present (n=85)
Number of subjects: 3111

Group type: COMPARATOR
Intervention: Basic model including age, pack-years, current smoking status, coronary and aorta calcium volume
Number of subjects: 3111
Study: 23238071

Group type: EXPERIMENTAL
Intervention: Conjunctival limbal autograft (AGCL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Simple excision with intraoperative mitomycin C (MMC)
Number of subjects: 60
Study: 21517190

Group type: EXPERIMENTAL
Intervention: Short-term dynamic psychotherapy (STDP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 0
Study: 19454870

Group type: COMPARATOR
Intervention: Lacosamide 400 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lacosamide 200 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lacosamide 600 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16778710

Group type: EXPERIMENTAL
Intervention: Rifampicin 450 mg/day for 7 days
Number of subjects: 13

Group type: COMPARATOR
Intervention: Matched placebo for 7 days
Number of subjects: 13
Study: 15342446

Group type: EXPERIMENTAL
Intervention: Current hormone replacement therapy (HRT) users
Number of subjects: 1271

Group type: EXPERIMENTAL
Intervention: Ex-users of hormone replacement therapy (HRT)
Number of subjects: 1271

Group type: EXPERIMENTAL
Intervention: Never users of hormone replacement therapy (HRT)
Number of subjects: 1271

Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 1271

Group type: EXPERIMENTAL
Intervention: Current HRT use
Number of subjects: 1271
Study: 11777111

Group type: EXPERIMENTAL
Intervention: Dietary-negative affect subtype (33%)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Pure dietary subtype (67%)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Cluster-analytic subtyping at 2 time points (73 patients)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Alternative subtyping approaches (by major depression or binge eating frequency)
Number of subjects: 101
Study: 9297650

Group type: EXPERIMENTAL
Intervention: Tannin‐fluoride preparation
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional autopolymerizing resin
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 31
Study: 8339574

Group type: EXPERIMENTAL
Intervention: Conventional surface-landmark guidance with a 30‐cm catheter
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Right atrial electrocardiography-guided technique with a 20‐cm central venous catheter
Number of subjects: 162

Group type: COMPARATOR
Intervention: Conventional techniques with a 30‐cm catheter
Number of subjects: 162
Study: 2942167

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB) 120 micrograms delivered by a metered dose inhaler (MDI)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB) 125 micrograms delivered by a gas driven nebulizer
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB) 500 micrograms delivered by a gas driven nebulizer
Number of subjects: 32

Group type: COMPARATOR
Intervention: Baseline assessment
Number of subjects: 32
Study: 31460693

Group type: EXPERIMENTAL
Intervention: New-generation drug-eluting stents (DES)
Number of subjects: 69
Study: 31175874

Group type: EXPERIMENTAL
Intervention: EMR with coagulation
Number of subjects: 569

Group type: COMPARATOR
Intervention: EMR (control)
Number of subjects: 569
Study: 27026339

Group type: COMPARATOR
Intervention: Umeclidinium (UMEC) 15.6, 31.25, 62.5, 125, and 250 mcg once daily; 15.6 and 31.25 mcg twice daily
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 26293451

Group type: EXPERIMENTAL
Intervention: Aliskiren add-on therapy to ARB
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (ARB only)
Number of subjects: 83
Study: 24131073

Group type: EXPERIMENTAL
Intervention: 6-millisecond pulse duration and 9 J/cm²
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.45-millisecond pulse duration and 6 J/cm²
Number of subjects: 40
Study: 21529970

Group type: EXPERIMENTAL
Intervention: SST using VR role‐playing (SST‐VR)
Number of subjects: 91

Group type: COMPARATOR
Intervention: SST using traditional role‐playing (SST‐TR)
Number of subjects: 91
Study: 19886395

Group type: EXPERIMENTAL
Intervention: Oily fish diet
Number of subjects: 25

Group type: COMPARATOR
Intervention: Red meat diet
Number of subjects: 25
Study: 17056122

Group type: EXPERIMENTAL
Intervention: Valproate (500-1500 mg/day)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Olanzapine (7.5-15.0 mg/day)
Number of subjects: 21
Study: 16083201

Group type: EXPERIMENTAL
Intervention: Treated traction with routine conservative treatment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham traction with routine conservative treatment
Number of subjects: 120
Study: 11491207

Group type: EXPERIMENTAL
Intervention: Pioglitazone HCl 30 mg once daily
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study: 9923260

Group type: EXPERIMENTAL
Intervention: Multiple-barrier product
Number of subjects: 12

Group type: COMPARATOR
Intervention: Peri-Care
Number of subjects: 12

Group type: COMPARATOR
Intervention: Double-Guard
Number of subjects: 12
Study: 7846219

Group type: EXPERIMENTAL
Intervention: Metoprolol (14 mg)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Atropine sulfate (2 mg)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 3
Study: 3293415

Group type: EXPERIMENTAL
Intervention: Probucol combined with cholestyramine and dietary management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo combined with cholestyramine and dietary management
Number of subjects: 0
Study: 30475960

Group type: EXPERIMENTAL
Intervention: Apple flavanol extract (70 mg monomeric flavanols, 65 mg PCs)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Double dose of apple flavanol extract (140 mg monomeric flavanols, 130 mg PCs)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Apple PC extract (130 mg PCs, 6.5 mg monomeric flavanols)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 42
Study: 28331914

Group type: EXPERIMENTAL
Intervention: Multivitamin
Number of subjects: 0
Study: 25434501

Group type: EXPERIMENTAL
Intervention: Landiolol (0.125 mg/kg/min loading for 1 minute, then 0.04 mg/kg/min for 10 minutes)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Landiolol
Number of subjects: 240
Study: 23916188

Group type: EXPERIMENTAL
Intervention: Serious mental illness (SMI)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Serious mental illness (SMI) - African Americans
Number of subjects: 163

Group type: COMPARATOR
Intervention: General U.S. population - African Americans
Number of subjects: 163

Group type: COMPARATOR
Intervention: General U.S. population
Number of subjects: 163
Study: 20055762

Group type: EXPERIMENTAL
Intervention: Infraclavicular approach (IC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Axillary approach (AX)
Number of subjects: 80
Study: 18205960

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion (loading dose of 1 microg kg(‐1) for 10 min followed by a maintenance infusion of 0.4 microg kg(‐1) h(‐1))
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal saline infusion
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Number of subjects: 90
Study: 17181885

Group type: EXPERIMENTAL
Intervention: Dietary counselling and food products
Number of subjects: 209
Study: 14526957

Group type: EXPERIMENTAL
Intervention: Stable isotopes as tracers for ruthenium
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Stable isotopes as tracers for zirconium
Number of subjects: 6
Study: 11064784

Group type: EXPERIMENTAL
Intervention: Cambridge hospital at home service (CHAH)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 229
Study: 8836934

Group type: EXPERIMENTAL
Intervention: Entacapone (400 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Levodopa (LD) and carbidopa (300 mg and 75 mg respectively) with entacapone (400 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Levodopa (LD) and carbidopa (300 mg and 75 mg respectively) with placebo
Number of subjects: 12
Study: 1307270

Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diethylcarbamazine (DEC)
Number of subjects: 60
Study: 2934785

Group type: EXPERIMENTAL
Intervention: Aztreonam
Number of subjects: 2634

Group type: COMPARATOR
Intervention: Cefamandole
Number of subjects: 2634
Study: 30652941

Group type: EXPERIMENTAL
Intervention: Antidepressant medication (sertraline)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study: 29806132

Group type: EXPERIMENTAL
Intervention: Curcumin (500 mg capsules, total: 1,000 mg twice daily for 12 weeks)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 26497665

Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy plus cognitive behavioural therapy
Number of subjects: 61

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 61
Study: 24559684

Group type: EXPERIMENTAL
Intervention: Sciatic nerve block
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Posterior local anesthetic infiltration
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study: 22104388

Group type: EXPERIMENTAL
Intervention: Pediatric emergency medicine (PEM) physicians
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Emergency medicine (EM) physicians
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Overall emergency physicians
Number of subjects: 1000
Study: 20634175

Group type: EXPERIMENTAL
Intervention: Metformin plus colesevelam
Number of subjects: 286

Group type: COMPARATOR
Intervention: Metformin plus placebo
Number of subjects: 286
Study: 17624174

Group type: EXPERIMENTAL
Intervention: Calibra
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Duo Cement Plus
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: RelyX ARC
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Amalgambond Plus
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Dispersalloy (bonded with different intermediates)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Non-bonded amalgams
Number of subjects: 200
Study: 15288705

Group type: COMPARATOR
Intervention: Control boys
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control girls
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Turner Syndrome girls
Number of subjects: 52
Study: 11413004

Group type: EXPERIMENTAL
Intervention: Prism adaptation to rightward optical deviation (3 min duration)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Prism adaptation to leftward optical deviation (3 min duration)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Neutral prisms (3 min duration)
Number of subjects: 15
Study: 9007666

Group type: EXPERIMENTAL
Intervention: Methylprednisolone, 30 mg/kg administered before CPB commencement (group MP)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (group C)
Number of subjects: 16
Study: 8215522

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 200 micrograms/day
Number of subjects: 398

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate 400 micrograms/day
Number of subjects: 398
Study: 2960478

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31838046

Group type: EXPERIMENTAL
Intervention: Peanut exposure during double-blind, placebo-controlled peanut challenges
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peanut exposure
Number of subjects: 0
Study: 29536338

Group type: EXPERIMENTAL
Intervention: Semaglutide 0.5 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Semaglutide 1.0 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Semaglutide 0.25 mg
Number of subjects: 44
Study: 27310479

Group type: EXPERIMENTAL
Intervention: Crazy Taxi videogame
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insight brain training game
Number of subjects: 0
Study: 24441673

Group type: COMPARATOR
Intervention: Topically applied tazarotene for BCC chemoprevention
Number of subjects: 70

Group type: COMPARATOR
Intervention: Topically applied tazarotene for chemotherapy of BCC lesions
Number of subjects: 70
Study: 23613639

Group type: EXPERIMENTAL
Intervention: Endoscopic papillary balloon intermittent dilatation (EPBID)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Endoscopic sphincterotomy (EST)
Number of subjects: 206
Study: 20646350

Group type: EXPERIMENTAL
Intervention: Sublingual allergoid immunotherapy (allergoid SLIT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard drug therapy (Control)
Number of subjects: 30
Study: 18799425

Group type: EXPERIMENTAL
Intervention: Pain and depression
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Pain and anxiety
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Pain, depression, and anxiety
Number of subjects: 500

Group type: COMPARATOR
Intervention: Pain only
Number of subjects: 500
Study: 16337781

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Budesonide/formoterol 320/9 microg
Number of subjects: 20
Study: 12819076

Group type: EXPERIMENTAL
Intervention: Zinc sulfate (45 mg elemental zinc thrice daily for 9 days starting 2 days before each vaccine dose)
Number of subjects: 30
Study: 12000041

Group type: EXPERIMENTAL
Intervention: Ionic low osmolar contrast medium
Number of subjects: 454

Group type: COMPARATOR
Intervention: Nonionic low osmolar contrast medium
Number of subjects: 454
Study: 9050361

Group type: EXPERIMENTAL
Intervention: Repetitive magnetic stimulation
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 38
Study: 1610710

Group type: EXPERIMENTAL
Intervention: 250 mg fusidic acid, administered twice daily for 6 days
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 500 mg fusidic acid, administered twice daily for 6 days
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both dosages of fusidic acid
Number of subjects: 8
Study: 6092554

Group type: EXPERIMENTAL
Intervention: Alternating chemotherapy (VAM)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Sequential chemotherapy (POCC)
Number of subjects: 147
Study: 30115656

Group type: EXPERIMENTAL
Intervention: Chlorambucil (7 mg/m2 daily), rituximab (375 mg/m2 cycle 1 and 500 mg/m2 cycles 2-6), and individually-dosed lenalidomide (escalated from 2.5 mg to 10 mg) for 6 cycles followed by 10 mg lenalidomide monotherapy for 6 months (induction-I and induction-II)
Number of subjects: 53
Study: 30172196

Group type: EXPERIMENTAL
Intervention: Active filtration for 2 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sham filtration for 2 weeks
Number of subjects: 35
Study: 26843153

Group type: EXPERIMENTAL
Intervention: Iron supplementation for 28 days during antimalarial treatment
Number of subjects: 239

Group type: COMPARATOR
Intervention: No iron supplementation during antimalarial treatment
Number of subjects: 239
Study: 26167945

Group type: EXPERIMENTAL
Intervention: Motivational interviewing plus personalized feedback (brief motivational interventions; BMI)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Computerized personalized feedback intervention (electronic check‐up to go; e‐CHUG)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Assessment only
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: BMI and e‐CHUG
Number of subjects: 133
Study: 22476807

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Meloxicam
Number of subjects: 162
Study: 20100748

Group type: EXPERIMENTAL
Intervention: Family Care (FC)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 366
Study: 18554192

Group type: EXPERIMENTAL
Intervention: Enhanced AAI/R pacing (MVP)
Number of subjects: 121

Group type: COMPARATOR
Intervention: DDD/R pacing (Control)
Number of subjects: 121
Study: 15682367

Group type: EXPERIMENTAL
Intervention: New method of quantification (TPD)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Visual scoring
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard quantification
Number of subjects: 80